On Tuesday, Lincoln National Corporation(NYSE:LNC)’s shares declined -4.92% to $48.30.
Lincoln Financial Group (LNC) declared the next generation of its Lincoln AssetEdge® Variable Universal Life (VUL) insurance offering, featuring expanded investment options for tax-efficient cash accumulation with downside protection, and supplemental income potential, as well as life insurance protection.
In addition to offering clients an income tax-free death benefit and more than 80 market-driven variable investment options from the Lincoln Elite Series of Funds for maximum growth potential, Lincoln AssetEdge® VUL now offers three indexed accounts for moderate growth potential with guaranteed downside protection, and a fixed account for more conservative, predictable growth. Clients have the ability to adjust investment allocations over time to align with changing needs and financial goals.
Lincoln National Corporation, through its auxiliaries, engages in multiple insurance and retirement businesses in the United States. It operates through Annuities, Retirement Plan Services, Life Insurance, and Group Protection segments.
Parker-Hannifin Corp(NYSE:PH)’s shares dropped -1.86% to $105.68.
Parker Hannifin Corporation (PH), the global leader in motion and control technologies, recently declared that Jeff Cullman, Vice President and President - Hydraulics Group, will retire effective October 1, 2015 after 36 years of dedicated service to the company. Separately, the company recently declared that Bob Bond, Vice President and President - Fluid Connectors Group, has been elected to a newly created position as Vice President - eBusiness, IoT and Services, effective September 1, 2015. As a result of these changes, the company is making a number of related changes for several operating groups, effective September 1, 2015.
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. It operates through two segments, Diversified Industrial and Aerospace Systems. The Diversified Industrial segment provides pneumatic, fluidic, and electromechanical components and systems; filters, systems, and diagnostics solutions to monitor and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors, which control, transmit, and contain fluid; hydraulic components and systems for builders and users of industrial and mobile machinery and equipment; critical flow components for process instrumentation, healthcare, and ultra-high-purity applications, in addition to components for use in refrigeration and air conditioning systems, and in fluid control applications for processing, fuel dispensing, beverage dispensing, and mobile emissions; and static and dynamic sealing devices.
At the end of Tuesday’s trade, FedEx Corporation(NYSE:FDX)‘s shares dipped -0.02% to $148.00.
FedEx Express, a wholly owned partner of FedEx Corp. (FDX), agreed to purchase 50 additional 767-300F aircraft from The Boeing Company as it continues to modernize its aircraft fleet to more effectively serve its customers. In addition to the 50 confirmed orders, FedEx also has options to purchase a total of 50 767F aircraft.
The 50 firm-order aircraft will be delivered from fiscal 2018 through fiscal 2023. Total capital spending for fiscal 2016 remains at $4.6 billion. The impact to capital spending in fiscal 2017 from this new order is immaterial. With this order, FedEx Express now holds a total of 106 firm orders for 767Fs from The Boeing Company through fiscal 2023.
FedEx Corporation provides transportation, e-commerce, and business services in the United States and internationally. The company’s FedEx Express segment provides various shipping services for the delivery of packages and freight; international trade services specializing in customs brokerage, and ocean and air freight forwarding services; international trade advisory services, such as assistance with the customs-trade partnership against terrorism program; and customs clearance services, in addition to global trade data, an information tool that allows customers to track and manage imports.
ZIOPHARM Oncology Inc.(NASDAQ:ZIOP), ended its Tuesday’s trading session with -1.61% loss, and closed at $8.57.
ZIOPHARM Oncology, Inc. (ZIOP) declared financial results for the second quarter ended June 30, 2015, and offered an update on the company’s recent activities.
Recent Highlights
Ad-RTS-hIL-12
Ad-RTS-hIL-12 is a gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response, using the RheoSwitch Therapeutic System(R) (RTS(R)) gene switch. In April 2015, ZIOPHARM declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 and veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. In May 2015, the Company declared the initiation of a multi-center Phase 1 study of Ad-RTS-hIL-12 and veledimex in patients with recurrent or progressive glioblastoma multiforme, a form of brain cancer.
Both gene therapy trials, which are being conducted at leading centers across the U.S., are presently open and accruing patients. The Company anticipates that early results from each study will be presented at scientific meetings preceding to year end.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
